Understanding CAR Tcell therapy (November 2020)

Presented by Dr Michael Dickinson, Peter MacCallum Cancer Centre & Royal Melbourne Hospital

Hosted by Donna Gairns, National Nurse Manager, Lymphoma Australia

Dr Michael Dickinson, is a Consultant Haematologist at Peter MacCallum Cancer Centre & Royal Melbourne Hospital and disease group lead for aggressive lymphoma. Dr Dickinson has a special interest in lymphoma and is leading the development of new targeted, nonchemotherapy drugs as the principal investigator of many trials of new treatments. He is
the local investigator on a range of CAR Tcell therapy trials. Dr Dickinson has been instrumental in helping in the recent approval of publicly funded CAR Tcell therapy to Australian patients.

CAR Tcell therapy is a relatively new therapy that has gained a lot of attention in the treatment of lymphoma/CLL in recent years. Dr Dickinson provides a thorough presentation that is relevant to Australian lymphoma/CLL patients in November 2020 in an exciting area that is changing rapidly.

The presentation includes:
What is CAR Tcell therapy?
How does CAR Tcell therapy work?
What is the process?
Side effects of CAR Tcell therapy
What subtypes are currently being treated in Australia & worldwide
CAR Tcell therapy funding in Australia
Clinical trials available in Australia and around the world

For more information see the Lymphoma Australia website:
Chimeric antigen receptor (CAR) Tcell therapy:
https://www.lymphoma.org.au/aboutlym...
Chimeric antigen receptor (CAR) Tcell therapy fact sheet:
https://www.lymphoma.org.au/wpconten...

Contact the Lymphoma Australia Nurse Support line or email us:
Phone 1800 953 081
Email: [email protected]